These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 22185811

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.
    Vesikari T, Martin JC, Liss CL, Liska V, Schödel FP, Bhuyan PK.
    Pediatr Infect Dis J; 2011 Jul; 30(7):e109-13. PubMed ID: 21552183
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy infants.
    Romanò L, Zanetti AR.
    Expert Rev Vaccines; 2011 Sep; 10(9):1261-4. PubMed ID: 21919615
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults.
    Van Damme P, Minervini G, Liss CL, McCarson B, Vesikari T, Boslego JW, Bhuyan PK.
    Hum Vaccin; 2009 Feb; 5(2):92-7. PubMed ID: 18690015
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT.
    Vaccine; 2013 Nov 04; 31(46):5306-13. PubMed ID: 23727422
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Persistence of immunity in healthy adults aged ≥ 50 years primed with a hepatitis B vaccine 3 years previously.
    Sharma R, Ahlm C, Ostergaard L, Dowell A, Tran C, Thomas S, Eymin C.
    Hum Vaccin Immunother; 2015 Nov 04; 11(7):1709-16. PubMed ID: 25996838
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [The immunogenicity and safety of 10 microg recombination yeast hepatitis B vaccine applied in expanded population].
    Fu QP, He H, Li L, Chen HP, Zeng YX, Liu QL, Fang G, Dong CM, Guo SH, Li HG, Wang HY, He CS, Zhou SZ, Li L, Gu SN, Zhang ZF, Dai M.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Oct 04; 43(10):903-6. PubMed ID: 20137473
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.